Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
BioDelivery Sciences International, Inc.
BioDelivery Sciences Presenting Phase III Data on BEMA Fentanyl at American Pain Society Meeting
May 18th, 2008
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that four scientific posters for its lead product, BEMA(TM) Fentanyl, currently under review by the U.S. Food and Drug Administration (FDA) as a potential treatment for breakthrough pain (BTP) in opioid-tolerant patients with cancer, will be presented at the 27th Annual Scientific Meeting of the American Pain Society (APS), May 8-10, in Tampa, Florida. The scientific presentations will highlight the Phase III efficacy and safety data as well as the pharmacokinetics of BEMA(TM) Fentanyl. The posters will be presented on May 8 and 9. In January, BioDelivery Sciences announced that the FDA accepted for...
Source: Medical Letter on the CDC & FDA (2008-05-18)
|
